Search for: "CVS Pharmaceuticals, Inc."
Results 61 - 80
of 784
Sort by Relevance
|
Sort by Date
19 Oct 2020, 4:37 pm
Biofrontera Inc. et al, Case No. 1-18-cv-10568 (D. [read post]
18 Sep 2020, 7:49 am
Vox Media d/b/a SB Nation, No. 17-cv-01791(D.D.C. [read post]
18 Aug 2020, 11:30 am
Biogen, Inc., No. 2:17-cv-00715-WBS-EFB, 2017 WL 4012337, at *4-5 (E.D. [read post]
10 Aug 2020, 8:48 am
Golden Sunrise Nutraceutical, Inc., 2020 WL 4501968, No. 1:20-cv-01060-DAD-SKO (E.D. [read post]
31 Jul 2020, 9:40 am
Inc., No. 1:16-cv-987-RGA (D. [read post]
20 Jul 2020, 7:48 am
AKF, Inc., No. 19-cv-13562 (E.D. [read post]
29 Jun 2020, 12:41 pm
Wyeth Pharmaceuticals, Inc., U.S. [read post]
11 Jun 2020, 8:46 am
HouseCanary, Inc., No. 04-19-00044-CV (Tex. [read post]
4 Jun 2020, 10:10 am
In Ferring Pharmaceuticals Inc. et al v. [read post]
2 Jun 2020, 1:41 pm
One Int’l, Inc., No. 11-CV-05149-YGR, 2012 WL 4068632, at *3 (N.D. [read post]
13 May 2020, 2:03 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 592 n.10 (1993). [3] Id., citing Bourjaily v. [read post]
11 May 2020, 1:09 am
In my last post,[1] I praised Lee Mickus’s recent policy paper on amending Rule 702 for its persuasive force on the need for an amendment, as well as a source for helping lawyers anticipate common judicial dodges to a faithful application of the rule.[2] There are multiple dodges used by judicial dodgers, and it behooves litigants to recognize and anticipate them. [read post]
28 Apr 2020, 11:46 pm
by Olivia Henry and Nicholas Michelmore On 20 April 2020, Arnold LJ (sitting as a High Court Judge) gave judgment in the case between FibroGen Inc and Astellas Pharma Inc (together the “Claimants”), and Akebia Therapeutics Inc and Otsuka Pharmaceutical Company Limited (together the “Defendants”) which concerned six patents owned by FibroGen and exclusively licensed to Astellas (the “Patents”). [read post]
13 Apr 2020, 4:19 pm
John’s University Law School law professor Michael Perino.[14] According to Institutional Shareholder Services Inc., $5.84 billion in 2018 and $3.17 billion in 2019 was made available for distribution to investors that bought and sold shares in the U.S. capital markets.[15] ISS expects that figure to increase in 2020.[16] According to Jessica Erickson of the University of Richmond School of Law: To accurately distribute settlement funds in a securities class… [read post]
24 Mar 2020, 3:44 pm
The case is No. 20-cv-00799. [read post]
20 Mar 2020, 3:01 pm
Inovio Pharmaceuticals, Inc., March 12, 2020). [read post]
17 Mar 2020, 1:32 pm
Eco-Gel 200 ultrasound gel has been recalled by Eco-Med Pharmaceutical, Inc. due to bacterial contamination. [read post]
16 Mar 2020, 1:54 pm
Class Action Litig., No. 18-CV-2933, 2019 WL 1569792, at *8 (S.D.N.Y. [read post]
12 Mar 2020, 6:49 am
Agora Financial, LLC, 2020 WL 998734, No. 1:19-cv-3100-SAG (D. [read post]
2 Mar 2020, 11:04 am
Today (March 2, 2020) is the deadline for employers and other health benefit program sponsors, insurers, plan administrators and fiduciaries, health care providers, PBMs and other interested persons to comment on proposed federal rule change that would require insured health plans to count drug rebates and price concessions retained by pharmacy benefit managers (PBMs) as administrative expenses for purposes of determining if the issuing insurer is required to rebate premiums under the medical loss… [read post]
